BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

BioPorto A/S

BioPorto Diagnostics A/S

BioPorto Diagnostics Inc. (US)

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. 

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. 

To learn more about our products and their availability in your country, visit bioporto.com or follow our LinkedIn pages:

Outside the United States: https://www.linkedin.com/company/bioporto-diagnostics-a-s/

Within the US: https://www.linkedin.com/company/bioporto-diagnostics-inc-us/

Social Media Community Guidelines: https://bioporto.com/social-media/

Happy holidays everyone. We look forward to improving kidney care in #2024.
#AKI #PICU #NGAL4kids #KidneyHealthforAll

BioPorto Diagnostics A/S
BioPorto Diagnostics Inc. (US)

HC Andersen Capital hosts CEO Tony Pare with an update for the #investor community, addressing the common questions related to the FDA’s clearance of ProNephro AKI™ (NGAL) – the first biomarker assay for pediatric AKI risk assessment. #FDA #medicaldevices 
 
Watch the presentation at: https://bit.ly/48efBlU
 
Learn more about ProNephro AKI (NGAL) at: https://bit.ly/4aa7fOh

BioPorto is excited to announce that it has received FDA clearance for ProNephro AKI™ (NGAL). This is the first FDA-cleared assay for pediatric AKI risk assessment.
 
“Now, clinicians will have a new and biologically credible AKI test at their disposal,” said BioPorto’s Senior Medical Director Dr. Prasad Devarajan.
 
The road to clearance:
BioPorto’s NGAL test received FDA Breakthrough Device Designation in 2019. In 2020, at the height of COVID, the BioPorto team conducted a reference range study with local events across the USA – thank you to our families, friends, and new believers in saving kidneys. Thanks to 16 US children’s hospitals and their committed staff, the EARNEST cutoff study and GUIDANCE clinical trial with 660 patients enrolled were completed.
 
Extensive studies were run, and many reports were created by BioPorto’s R&D, medical, clinical and regulatory employees (past & present), culminating in a pediatric FDA De Novo submission in November 2022. Additional information was provided to FDA in June 2023 and in September 2023, the regulatory pathway was changed to a 510(k).
 
We recognize and appreciate our investors for their loyalty and financial support throughout the entire journey to FDA clearance.
 
Next step: US commercialization:
 “With the FDA’s 510(k) clearance for ProNephro AKI (NGAL) on the Roche cobas® c 501 analyzer, we are excited to launch BioPorto’s US commercialization efforts,” said Tony Pare, BioPorto’s Chief Executive Officer.

Learn more about ProNephro AKI at https://lnkd.in/e9HrtPZw

Nis Glavind Kruse and Helle Helena Kirkemann remind us that, “Thanksgiving is a universal value we can all embrace.” BioPorto gives thanks to our diverse and talented team, our loyal customers, investors, researchers, and clinicians, and our innovative and impactful NGAL products.

Happy Thanksgiving from the BioPorto team!
BioPorto Diagnostics Inc. (US)
BioPorto Diagnostics A/S


Congratulations to our #CEO Tony Pare on his profile in Insights Care. Tony’s #leadership in bringing #diagnostics to market is valued during this exciting time for the company. #medicaldevices 
https://bit.ly/47EESFC

BioPorto Diagnostics A/S
BioPorto Diagnostics Inc. (US)
 

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	16.63M -	18.71M 12.52%	20.38M 8.97%	20.72M 1.65%	25.16M 21.40%	26.02M 3.42%	26.62M 2.33%	23.20M 12.84%	24.25M 4.53%	28.97M 19.44%	30.96M 6.87%
cost of revenue	7.58M -	5.51M 27.35%	4.90M 11.00%	5.03M 2.55%	6.91M 37.40%	8.18M 18.45%	9.29M 13.59%	9.87M 6.16%	9.21M 6.61%	9.93M 7.75%	13.99M 40.93%
gross profit	9.04M -	13.20M 45.95%	15.48M 17.30%	15.69M 1.37%	18.25M 16.28%	17.84M 2.26%	17.33M 2.84%	13.34M 23.02%	15.04M 12.76%	19.04M 26.60%	16.97M 10.89%
selling and marketing expenses	5.97M -	9.40M 57.44%	8.88M 5.53%	18.04M 103.26%	18.55M 2.79%	20.93M 12.89%	39.27M 87.57%	20.79M 47.07%	17.38M 16.38%	21.22M 22.08%
general and administrative expenses	12.66M -	10.44M 17.56%	9.42M 9.78%	13.03M 38.32%	14.27M 9.49%	20.00M 40.22%	27.80M 38.99%	28.02M 0.77%	32.66M 16.56%	41.83M 28.09%
selling general and administrative expenses	18.63M -	19.84M 6.46%	18.30M 7.77%	31.07M 69.82%	32.81M 5.60%	40.94M 24.77%	67.07M 63.83%	48.80M 27.24%	50.04M 2.53%	63.05M 26.00%	52.84M 16.19%
research and development expenses	10.21M -	8.62M 15.63%	9.94M 15.41%	9.67M 2.77%	21.93M 126.81%	18.68M 14.84%	24.56M 31.48%	28.13M 14.53%	30.26M 7.58%	34.94M 15.47%	25.08M 28.22%
other expenses							-591K -	-474K 19.80%	-548K 15.61%	274K 150%	789K 187.96%
cost and expenses	36.43M -	33.96M 6.77%	33.14M 2.41%	45.77M 38.09%	61.65M 34.70%	67.80M 9.97%	100.92M 48.86%	86.79M 14.00%	89.51M 3.13%	107.91M 20.56%	91.12M 15.56%
operating expenses	28.84M -	28.45M 1.36%	28.24M 0.75%	40.74M 44.26%	54.74M 34.37%	59.62M 8.90%	91.63M 53.70%	76.93M 16.04%	80.30M 4.38%	97.99M 22.03%	77.13M 21.28%
interest expense	1.68M -	15K 99.10%	279K 1,760.00%	29K 89.61%	31K 6.90%	38K 22.58%	326K 757.89%	780K 139.26%	912K 16.92%	1.09M 19.30%	642K 40.99%
ebitda	-20.09M -	-14.81M 26.28%	-12.44M 16.05%	-24.48M 96.86%	-36.53M 49.22%	-41.04M 12.34%	-71.06M 73.17%	-62.06M 12.67%	-58.60M 5.58%	-73.91M 26.13%	-57.49M 22.22%
operating income	-19.80M -	-15.26M 22.96%	-12.76M 16.37%	-25.05M 96.31%	-36.49M 45.70%	-41.78M 14.49%	-74.30M 77.83%	-63.59M 14.41%	-65.25M 2.62%	-77.88M 19.34%	-60.16M 22.74%
depreciation and amortization	-289K -	444K 253.63%	324K 27.03%	567K 75%	-35K 106.17%	745K 2,228.57%	3.23M 334.23%	1.53M 52.70%	6.66M 335.03%	3.97M 40.41%	2.68M 32.48%
total other income expenses net	-2.07M -	159K 107.68%	-255K 260.38%	148K 158.04%	-570K 485.14%	164K 128.77%	52K 68.29%	-3.24M 6,338.46%	1.42M 143.62%	-3.67M 359.43%	-1.04M 71.59%
income before tax	-21.87M -	-15.10M 30.98%	-13.01M 13.80%	-24.90M 91.32%	-37.06M 48.86%	-41.62M 12.28%	-74.25M 78.41%	-66.83M 9.98%	-63.84M 4.48%	-81.55M 27.74%	-61.21M 24.94%
income tax expense	-1.25M -	-2.17M 73.68%	-2.28M 5.11%	-2.10M 8.02%	-4.82M 129.68%	-3.57M 25.97%	-4.61M 29.03%	-5.27M 14.48%	-6.73M 27.60%	-5.62M 16.40%	-4.88M 13.25%
net income	-20.62M -	-12.93M 37.32%	-10.73M 16.97%	-22.80M 112.45%	-32.24M 41.42%	-38.05M 18.00%	-69.64M 83.04%	-61.56M 11.60%	-57.11M 7.23%	-75.92M 32.93%	-56.33M 25.81%
weighted average shs out	99.65M -	148.41M 48.93%	153.17M 3.21%	164.97M 7.71%	182.02M 10.33%	197.25M 8.36%	255.47M 29.52%	213.54M 16.41%	278.05M 30.21%	331.20M 19.12%	358.50M 8.24%
weighted average shs out dil	99.65M -	148.41M 48.93%	153.17M 3.21%	164.97M 7.71%	182.02M 10.33%	197.25M 8.36%	255.47M 29.52%	213.54M 16.41%	278.05M 30.21%	331.20M 19.12%	358.50M 8.24%
eps	-0.21 -	-0.09 58.52%	-0.07 19.52%	-0.14 99.71%	-0.18 28.57%	-0.19 5.56%	-0.27 42.11%	-0.29 7.41%	-0.21 27.59%	-0.23 9.52%	-0.16 30.43%
epsdiluted	-0.21 -	-0.09 58.52%	-0.07 19.52%	-0.14 99.71%	-0.18 28.57%	-0.19 5.56%	-0.27 42.11%	-0.29 7.41%	-0.21 27.59%	-0.23 9.52%	-0.16 30.43%

COM:BIOPORTO

BioPorto

Last Close

1.78

08/11 11:26

Market Cap

913.02M

Beta: -

Volume Today

288.56K

Avg: -

Preview